<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01747330</url>
  </required_header>
  <id_info>
    <org_study_id>M13-277</org_study_id>
    <nct_id>NCT01747330</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency</brief_title>
  <official_title>An Open Label, Multicenter Study Evaluating Safety and Tolerability of Creon Micro in Pediatric Subjects From at Least One Month to Less Than Four Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Products</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of Creon micro in
      children younger than four years with pancreatic exocrine insufficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective open-label, multi-center study evaluating safety and tolerability of Creon
      Micro in pediatric subjects from at least one month to less than four years of age with
      Pancreatic Exocrine Insufficiency (PEI) due to Cystic Fibrosis (CF). Referring to the
      European Medicines Agency (EMEA) pediatric age criteria for the purpose of the study,
      subjects are categorized as infants and toddlers (&lt; 2 years) and children, (2 years to &lt; 4
      years). In total, 40 subjects will be enrolled (20 subjects in each age subgroup). Subjects
      receive their prescribed pancreatic enzyme supplementation at the individual dose until start
      of treatment with Creon Micro, if the subjects were on pancreatic enzyme supplementation
      before start of the study. Subjects will be treated with Creon Micro during the study. The
      treatment duration is 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body Weight</measure>
    <time_frame>3 months</time_frame>
    <description>change from baseline at day 84</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Height</measure>
    <time_frame>3 months</time_frame>
    <description>change from baseline at day 84</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stool Frequency</measure>
    <time_frame>3 months</time_frame>
    <description>Average daily stool frequency during treatment period: Number of bowel movements per day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stool Consistency</measure>
    <time_frame>3 months</time_frame>
    <description>Assessment of stool consistency by the caregiver on a daily basis: hard, formed/normal, soft, watery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject's Acceptance of Treatment</measure>
    <time_frame>3 months</time_frame>
    <description>Acceptance to Creon Micro. The caregiver should give his/her opinion based on the following scale: very good, good, moderate, and unsatisfactory.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Adverse Events</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>3 months</time_frame>
    <description>Change from Baseline at Day 84</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Findings During Physical Examination</measure>
    <time_frame>3 months</time_frame>
    <description>A physical examination was conducted by the physician. All abnormal findings were recorded as medical histories if present prior to start of study drug or as AEs otherwise. There was no separate documentation of physical examination findings in this study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Relevant Safety Laboratory Values</measure>
    <time_frame>3 months</time_frame>
    <description>(hematology: hemoglobin, hematocrit, RBC count, WBC count, platelet count; biochemistry: glucose (fasting), creatinine, alkaline phosphatase, total bilirubin, ALAT (alanine amino transferase), ASAT (aspartate amino transferase), gamma-glutamyl transferase, uric acid, calcium, phosphate, potassium, serum pancreatic lipase; urinalysis (dipstick): glucose, blood, albumin, pH)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Pancreatic Exocrine Insufficiency</condition>
  <arm_group>
    <arm_group_label>Creon micro, minimicrospheres</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pancreatin</intervention_name>
    <description>Doses of Pancreatin &lt;2500 lipase u/kg/feed or &lt;4000 lipase U/g fat/intake or &lt;10000 lipase U/kg/day given orally are used</description>
    <arm_group_label>Creon micro, minimicrospheres</arm_group_label>
    <other_name>Creon micro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children younger than four years with confirmed cystic fibrosis diagnosis and a body
             weight of at least 2 kilograms

        Exclusion Criteria:

          -  Ileus or acute abdomen

          -  history of fibrosing colonopathy

          -  history of distal ileal obstruction without surgery

          -  solid organ transplant or surgery affecting the large bowel, other than appendectomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>4 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suntje Sander-Struckmeier, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 80716</name>
      <address>
        <city>Barnaul</city>
        <zip>656019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 80693</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 80698</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630091</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 80713</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 80715</name>
      <address>
        <city>Orenburg</city>
        <zip>460000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 80694</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194156</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 80714</name>
      <address>
        <city>Tomsk</city>
        <zip>634050</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 80697</name>
      <address>
        <city>Voronezh</city>
        <zip>394036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 80696</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2012</study_first_submitted>
  <study_first_submitted_qc>December 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2012</study_first_posted>
  <results_first_submitted>December 23, 2013</results_first_submitted>
  <results_first_submitted_qc>June 13, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 15, 2014</results_first_posted>
  <last_update_submitted>June 13, 2014</last_update_submitted>
  <last_update_submitted_qc>June 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cystic fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Creon Micro, Minimicrospheres</title>
          <description>Pancreatin: Doses of Pancreatin &lt;2500 lipase u/kg/feed or &lt;4000 lipase U/g fat/intake or &lt;10000 lipase U/kg/day given orally are used</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Creon Micro, Minimicrospheres</title>
          <description>Pancreatin: Doses of pancreatin &lt;2500 lipase u/kg/feed or &lt;4000 lipase u/g fat/intake or &lt;10000 lipase u/kg/day given orally are used</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.7" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Body Weight</title>
        <description>change from baseline at day 84</description>
        <time_frame>3 months</time_frame>
        <population>Full Analysis subject sample</population>
        <group_list>
          <group group_id="O1">
            <title>Creon Micro, Minimicrospheres</title>
            <description>Pancreatin: Doses of Pancreatin &lt;2500 lipase u/kg/feed or &lt;4000 lipase U/g fat/intake or &lt;10000 lipase U/kg/day given orally are used</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight</title>
          <description>change from baseline at day 84</description>
          <population>Full Analysis subject sample</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Height</title>
        <description>change from baseline at day 84</description>
        <time_frame>3 months</time_frame>
        <population>Full Analysis subject sample</population>
        <group_list>
          <group group_id="O1">
            <title>Creon Micro, Minimicrospheres</title>
            <description>Pancreatin: Doses of Pancreatin &lt;2500 lipase u/kg/feed or &lt;4000 lipase U/g fat/intake or &lt;10000 lipase U/kg/day given orally are used</description>
          </group>
        </group_list>
        <measure>
          <title>Height</title>
          <description>change from baseline at day 84</description>
          <population>Full Analysis subject sample</population>
          <units>m</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.026" spread="0.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Stool Frequency</title>
        <description>Average daily stool frequency during treatment period: Number of bowel movements per day</description>
        <time_frame>3 months</time_frame>
        <population>Full Analysis subject sample</population>
        <group_list>
          <group group_id="O1">
            <title>Creon Micro, Minimicrospheres</title>
            <description>Pancreatin: Doses of Pancreatin &lt;2500 lipase u/kg/feed or &lt;4000 lipase U/g fat/intake or &lt;10000 lipase U/kg/day given orally are used</description>
          </group>
        </group_list>
        <measure>
          <title>Stool Frequency</title>
          <description>Average daily stool frequency during treatment period: Number of bowel movements per day</description>
          <population>Full Analysis subject sample</population>
          <units>Bowel movements per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Stool Consistency</title>
        <description>Assessment of stool consistency by the caregiver on a daily basis: hard, formed/normal, soft, watery</description>
        <time_frame>3 months</time_frame>
        <population>Full Analysis subject sample</population>
        <group_list>
          <group group_id="O1">
            <title>Creon Micro, Minimicrospheres</title>
            <description>Pancreatin: Doses of Pancreatin &lt;2500 lipase u/kg/feed or &lt;4000 lipase U/g fat/intake or &lt;10000 lipase U/kg/day given orally are used</description>
          </group>
        </group_list>
        <measure>
          <title>Stool Consistency</title>
          <description>Assessment of stool consistency by the caregiver on a daily basis: hard, formed/normal, soft, watery</description>
          <population>Full Analysis subject sample</population>
          <units>% of days with normal stool consistency</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.4" spread="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subject's Acceptance of Treatment</title>
        <description>Acceptance to Creon Micro. The caregiver should give his/her opinion based on the following scale: very good, good, moderate, and unsatisfactory.</description>
        <time_frame>3 months</time_frame>
        <population>Full Analysis subject sample</population>
        <group_list>
          <group group_id="O1">
            <title>Creon Micro, Minimicrospheres</title>
            <description>Pancreatin: Doses of Pancreatin &lt;2500 lipase u/kg/feed or &lt;4000 lipase U/g fat/intake or &lt;10000 lipase U/kg/day given orally are used</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Acceptance of Treatment</title>
          <description>Acceptance to Creon Micro. The caregiver should give his/her opinion based on the following scale: very good, good, moderate, and unsatisfactory.</description>
          <population>Full Analysis subject sample</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>very good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unsatisfactory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Adverse Events</title>
        <time_frame>4 months</time_frame>
        <population>Full Analysis subject sample</population>
        <group_list>
          <group group_id="O1">
            <title>Creon Micro, Minimicrospheres</title>
            <description>Pancreatin: Doses of Pancreatin &lt;2500 lipase u/kg/feed or &lt;4000 lipase U/g fat/intake or &lt;10000 lipase U/kg/day given orally are used</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Events</title>
          <population>Full Analysis subject sample</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse</title>
        <description>Change from Baseline at Day 84</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Creon Micro, Minimicrospheres</title>
            <description>Pancreatin: Doses of Pancreatin &lt;2500 lipase u/kg/feed or &lt;4000 lipase U/g fat/intake or &lt;10000 lipase U/kg/day given orally are used</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse</title>
          <description>Change from Baseline at Day 84</description>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Findings During Physical Examination</title>
        <description>A physical examination was conducted by the physician. All abnormal findings were recorded as medical histories if present prior to start of study drug or as AEs otherwise. There was no separate documentation of physical examination findings in this study.</description>
        <time_frame>3 months</time_frame>
        <population>Full Analysis subject sample</population>
        <group_list>
          <group group_id="O1">
            <title>Creon Micro, Minimicrospheres</title>
            <description>Pancreatin: Doses of Pancreatin &lt;2500 lipase u/kg/feed or &lt;4000 lipase U/g fat/intake or &lt;10000 lipase U/kg/day given orally are used</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Findings During Physical Examination</title>
          <description>A physical examination was conducted by the physician. All abnormal findings were recorded as medical histories if present prior to start of study drug or as AEs otherwise. There was no separate documentation of physical examination findings in this study.</description>
          <population>Full Analysis subject sample</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Relevant Safety Laboratory Values</title>
        <description>(hematology: hemoglobin, hematocrit, RBC count, WBC count, platelet count; biochemistry: glucose (fasting), creatinine, alkaline phosphatase, total bilirubin, ALAT (alanine amino transferase), ASAT (aspartate amino transferase), gamma-glutamyl transferase, uric acid, calcium, phosphate, potassium, serum pancreatic lipase; urinalysis (dipstick): glucose, blood, albumin, pH)</description>
        <time_frame>3 months</time_frame>
        <population>Full Analysis subject sample</population>
        <group_list>
          <group group_id="O1">
            <title>Creon Micro, Minimicrospheres</title>
            <description>Pancreatin: Doses of Pancreatin &lt;2500 lipase u/kg/feed or &lt;4000 lipase U/g fat/intake or &lt;10000 lipase U/kg/day given orally are used</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Relevant Safety Laboratory Values</title>
          <description>(hematology: hemoglobin, hematocrit, RBC count, WBC count, platelet count; biochemistry: glucose (fasting), creatinine, alkaline phosphatase, total bilirubin, ALAT (alanine amino transferase), ASAT (aspartate amino transferase), gamma-glutamyl transferase, uric acid, calcium, phosphate, potassium, serum pancreatic lipase; urinalysis (dipstick): glucose, blood, albumin, pH)</description>
          <population>Full Analysis subject sample</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Creon Micro, Minimicrospheres</title>
          <description>Pancreatin: Doses of Pancreatin &lt;2500 lipase u/kg/feed or &lt;4000 lipase U/g fat/intake or &lt;10000 lipase U/kg/day given orally are used</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal spastic and hypermotility disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infections NEC</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>upper respiratory tract infections</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Director Clinical Services</name_or_title>
      <organization>Abbott</organization>
      <email>taco.baardman@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

